Similar articles for PMID: 31811061

Year	Number of Results
2003	2
2004	1
2006	3
2007	1
2008	2
2009	1
2010	2
2011	2
2012	2
2013	9
2014	6
2015	15
2016	13
2017	12
2018	11
2019	16
2020	12
2021	2
2022	2
2023	0

1

Assessing PET Parameters in Oncologic ¹⁸F-FDG Studies.

Sarikaya I, Sarikaya A. Sarikaya I, et al. J Nucl Med Technol. 2020 Sep;48(3):278-282. doi: 10.2967/jnmt.119.236109. Epub 2019 Dec 6. J Nucl Med Technol. 2020. PMID: 31811061 Free article. Review.

2

The clinical value of texture analysis of dual-time-point ¹⁸F-FDG-PET/CT imaging to differentiate between ¹⁸F-FDG-avid benign and malignant pulmonary lesions.

Nakajo M, Jinguji M, Aoki M, Tani A, Sato M, Yoshiura T. Nakajo M, et al. Eur Radiol. 2020 Mar;30(3):1759-1769. doi: 10.1007/s00330-019-06463-7. Epub 2019 Nov 14. Eur Radiol. 2020. PMID: 31728684

3

Metabolic Tumor Burden Assessed by Dual Time Point [¹⁸F]FDG PET/CT in Locally Advanced Breast Cancer: Relation with Tumor Biology.

Garcia-Vicente AM, Pérez-Beteta J, Pérez-García VM, Molina D, Jiménez-Londoño GA, Soriano-Castrejón A, Martínez-González A. Garcia-Vicente AM, et al. Mol Imaging Biol. 2017 Aug;19(4):636-644. doi: 10.1007/s11307-016-1034-x. Mol Imaging Biol. 2017. PMID: 27981471

4

Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients.

Dimitrakopoulou-Strauss A, Strauss L. Dimitrakopoulou-Strauss A, et al. Hell J Nucl Med. 2006 Jan-Apr;9(1):10-21. Hell J Nucl Med. 2006. PMID: 16617388

5

Comparative Performance of ¹⁸F-FDG PET/MRI and ¹⁸F-FDG PET/CT in Detection and Characterization of Pulmonary Lesions in 121 Oncologic Patients.

Sawicki LM, Grueneisen J, Buchbender C, Schaarschmidt BM, Gomez B, Ruhlmann V, Wetter A, Umutlu L, Antoch G, Heusch P. Sawicki LM, et al. J Nucl Med. 2016 Apr;57(4):582-6. doi: 10.2967/jnumed.115.167486. Epub 2016 Jan 7. J Nucl Med. 2016. PMID: 26742715 Free article.

6

Quantitative analysis of image metrics for reduced and standard dose pediatric ¹⁸F-FDG PET/MRI examinations.

Zucchetta P, Branchini M, Zorz A, Bodanza V, Cecchin D, Paiusco M, Bui F. Zucchetta P, et al. Br J Radiol. 2019 Mar;92(1095):20180438. doi: 10.1259/bjr.20180438. Epub 2019 Jan 23. Br J Radiol. 2019. PMID: 30673306 Free PMC article. Clinical Trial.

7

Does whole-body Patlak ¹⁸F-FDG PET imaging improve lesion detectability in clinical oncology?

Fahrni G, Karakatsanis NA, Di Domenicantonio G, Garibotto V, Zaidi H. Fahrni G, et al. Eur Radiol. 2019 Sep;29(9):4812-4821. doi: 10.1007/s00330-018-5966-1. Epub 2019 Jan 28. Eur Radiol. 2019. PMID: 30689031

8

Are lesion features reproducible between ¹⁸F-FDG PET/CT images when acquired on analog or digital PET/CT scanners?

Constantino CS, Oliveira FPM, Silva M, Oliveira C, Castanheira JC, Silva Â, Vaz SC, Vieira P, Costa DC. Constantino CS, et al. Eur Radiol. 2021 May;31(5):3071-3079. doi: 10.1007/s00330-020-07390-8. Epub 2020 Oct 30. Eur Radiol. 2021. PMID: 33125562

9

Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials.

Weber WA, Gatsonis CA, Mozley PD, Hanna LG, Shields AF, Aberle DR, Govindan R, Torigian DA, Karp JS, Yu JQ, Subramaniam RM, Halvorsen RA, Siegel BA; ACRIN 6678 Research team; MK-0646-008 Research team. Weber WA, et al. J Nucl Med. 2015 Aug;56(8):1137-43. doi: 10.2967/jnumed.114.147728. Epub 2015 Apr 23. J Nucl Med. 2015. PMID: 25908829 Free PMC article. Clinical Trial.

10

Lymph node standardized uptake values at pre-treatment ¹⁸F-fluorodeoxyglucose positron emission tomography as a valuable prognostic factor for distant metastasis in nasopharyngeal carcinoma.

Jeong Y, Baek S, Park JW, Joo JH, Kim JS, Lee SW. Jeong Y, et al. Br J Radiol. 2017 Mar;90(1071):20160239. doi: 10.1259/bjr.20160239. Epub 2016 Dec 23. Br J Radiol. 2017. PMID: 28008776 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed